The subject of this publication is the conclusion of contracts in accordance with Section 130a (8) SGB V for the following active substances / combinations of active substances in the context of a so-called open house procedure:

atenolol (C07AB03)

Calcipotriol & Betamethasone (D05AX22) without dosage form ointment

carbamazepine (N03AF01)

Lenalidomide (L04AX04)

L-thyroxine sodium (H03AA01)

Methylprednisolone (H02AB04)

Olmesartan medoxomil & hydrochlorothiazide (C09DA28)

Sunitinib (L01EX01)

theophylline (R03DA04)

All suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V for the above-mentioned active ingredients / active ingredient combinations, subject to standardized contractual conditions and a standardized access procedure.

The earliest start of the contract is 01.02.2022. On this basis, the contract period is a maximum of 24 months.

Providing uniform contractual terms and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a discount contract in accordance with Section 130a (8) SGB V for the active substances / combinations of active substances mentioned.

The earliest start of the contract is 01.02.2022. On this basis, the contract period is a maximum of 24 months.